Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1
The secretory function of pancreatic beta cells is synergistically stimulated by two signalling pathways which mediate the effects of nutrients and hormones such as glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or glucagon. These hormones are known to activate adenylyl cyclase in beta cells. We examined the type of adenylyl cyclase that is associated with this synergistic interaction.
Insulin release, cAMP production, adenylyl cyclase activity, mRNA and protein expression were measured in fluorescence-activated cell sorter-purified rat beta cells and in the rat beta-cell lines RINm5F, INS-1 832/13 and INS-1 832/2.
In primary beta cells, glucagon and GLP-1 synergistically potentiate the stimulatory effect of 20 mmol/l glucose on insulin release and cAMP production. Both effects are abrogated in the presence of the L-type Ca2+-channel blocker verapamil. The cAMP-producing activity of adenylyl cyclase in membranes from RINm5F cells is synergistically increased by Ca2+-calmodulin and recombinant GTPγS-activated Gsα-protein subunits. This type of regulation is characteristic for type I and type VIII AC isoforms. Consistent with this functional data, AC mRNA analysis shows abundant expression of type VI AC, four splice variants of type VIII AC and low expression level of type I AC in beta cells. Type VIII AC expression at the protein level was observed using immunoblots of RINm5F cell extracts.
This study identifies type VIII AC in insulin-secreting cells as one of the potential molecular targets for synergism between GLP-1 receptor mediated and glucose-mediated signalling.
- Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1
Volume 46, Issue 10 , pp 1383-1393
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Adenylyl cyclase
- beta cells
- cyclic AMP
- coincidence detection
- insulin release
- Industry Sectors
- Author Affiliations
- 1. Molecular Pharmacology Unit, Diabetes Research Center, Faculty of Medicine, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium
- 2. Promega Corporation, Madison, Wisconsin, USA